

Fitness and Virulence of a Coxsackievirus Mutant That Can Circumnavigate the Need for Phosphatidylinositol 4-Kinase Class III Beta

Hendrik Jan Thibaut, Hilde M. van der Schaar, Kjerstin H. W. Lanke, Erik Verbeken, Martin Andrews, Pieter Leyssen, Johan Neyts and Frank J. M. van Kuppeveld
J. Virol. 2014, 88(5):3048. DOI: 10.1128/JVI.03177-13.
Published Ahead of Print 26 December 2013.

Updated information and services can be found at:
<http://jvi.asm.org/content/88/5/3048>

These include:

REFERENCES

This article cites 10 articles, 7 of which can be accessed free at:
<http://jvi.asm.org/content/88/5/3048#ref-list-1>

CONTENT ALERTS

Receive: RSS Feeds, eTOCs, free email alerts (when new articles cite this article), [more»](#)

Information about commercial reprint orders: <http://journals.asm.org/site/misc/reprints.xhtml>
To subscribe to to another ASM Journal go to: <http://journals.asm.org/site/subscriptions/>

Fitness and Virulence of a Coxsackievirus Mutant That Can Circumnavigate the Need for Phosphatidylinositol 4-Kinase Class III Beta

Hendrik Jan Thibaut,^a Hilde M. van der Schaar,^a Kjerstin H. W. Lanke,^b Erik Verbeken,^c Martin Andrews,^d Pieter Leyssen,^e Johan Neyts,^e Frank J. M. van Kuppeveld^a

Department of Infectious Diseases & Immunology, Virology Division, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands^a; Department of Medical Microbiology, Radboud University Nijmegen Medical Centre, Nijmegen Centre for Molecular Life Sciences, Nijmegen, The Netherlands^b; Translational Cell & Tissue Research, Department of Imaging & Pathology, University of Leuven, Leuven, Belgium^c; Galapagos NV, Mechelen, Belgium^d; Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research, University of Leuven, Leuven, Belgium^e

Coxsackieviruses require phosphatidylinositol-4-kinase III β (PI4KIII β) for replication but can bypass this need by an H₅₇Y mutation in protein 3A (3A-H₅₇Y). We show that mutant coxsackievirus is not outcompeted by wild-type virus during 10 passages *in vitro*. In mice, the mutant virus proved as virulent as wild-type virus, even when mice were treated with a PI4KIII β inhibitor. Our data suggest that upon emergence, the 3A-H₅₇Y mutant has the fitness to establish a resistant population with a virulence similar to that of wild-type virus.

Enteroviruses, belonging to the family of the *Picornaviridae*, are small, positive-stranded RNA viruses and include many important human pathogens, including poliovirus, rhinovirus, coxsackievirus, and enterovirus 71. Since the genus *Enterovirus* comprises more than 250 (sero)types, the development of a pan-enterovirus vaccine will be unfeasible. Hence, the development of broad-spectrum antienteroviral drugs will be crucial for disease control. Like most RNA viruses, enteroviruses have a high mutation rate, resulting in a rapid emergence of drug resistance which eventually could lead to therapy failure. Drugs that target host factors that are crucial for virus replication are believed to impede this process. In recent years, several studies identified the essential membrane-modifying host cell factor phosphatidylinositol-4-kinase III β (PI4KIII β) as the target of broad-spectrum and highly potent inhibitors of enterovirus replication (1–8). However, following lengthy selection processes, coxsackievirus B3 (CVB3) mutants that are resistant to these inhibitors emerged and were shown to harbor single point mutations in the nonstructural protein 3A (4, 7, 8). The H₅₇Y mutation (3A-H₅₇Y) was identified most frequently and provided the strongest resistance against PI4KIII β inhibitors, as well as to depletion of this factor. This indicates that the mutant coxsackievirus can bypass this host factor and/or the need for its product, phosphatidylinositol-4-phosphate (PI4P), in cell culture (8).

The aim of this study was to explore the fitness of this mutant virus that can replicate independently of a host factor that is essential for the replication of the wild-type (wt) virus. We therefore studied whether the PI4KIII β -independent CVB3 mutant would be outgrown by wt virus within a mixed population. Previously, we performed a side-by-side comparison of the replication kinetics of both viruses in a single replication cycle *in vitro*. CVB3 3A-H₅₇Y was shown to grow with kinetics similar to those of the wt virus in the absence of a PI4KIII β inhibitor, suggesting that neither virus is able to outcompete the other (8). However, single-replication-cycle assays do not allow the detection of slight differences in the growth kinetics between two virus populations. Therefore, a multicycle growth-competition experiment was carried out, in which BGM cells were infected at a multiplicity of

infection of 0.001 with either wt CVB3 (strain Nancy) or CVB3 3A-H₅₇Y or were coinfecting with a mixture of the viruses at a ratio of 1:1 or 1:10 (wt/mutant). When cytopathic effect became apparent, the virus cultures were harvested by freeze-thawing and were titrated for infectious virus content. This process was repeated for 10 consecutive passages, and the ratio of mutant to wt virus was analyzed in every passage. To this end, viral RNA was isolated (Qiagen), reverse transcription (RT)-PCR was carried out using random hexamer primers (Roche), and the resulting cDNA (Fig. 1B and C, RT-PCR input) was then used as a template in a PCR. This reaction was performed with primers designed around the H₅₇Y mutation (forward primer, 5'-TAA TAC GAC TCA CTA TAG GAT AGC GTG GGG ACC ACG-3', and reverse primer, 5'-ATT AAC CTC CAC TTC CTC CTT GGC-3') to yield a 622-nucleotide (nt) DNA product. Next, a genotype-specific digestion was performed using restriction enzyme NspI, which only cleaves cDNA amplified from the wt CVB3, resulting in two fragments of 435 nt and 187 nt (Fig. 1A). Consequently, RNA isolated from CVB3 3A-H₅₇Y is represented by a single 622-nt product (Fig. 1A).

When wt virus was mixed with an equal amount of CVB3 3A-H₅₇Y, products from both viruses could be readily detected during 10 consecutive passages. We observed that after 3 passages, the viral RNA ratio shifted from favoring CVB3 3A-H₅₇Y toward favoring wt CVB3 (Fig. 1B and C). However, it remains unclear why this shift occurred. Nevertheless, CVB3 3A-H₅₇Y was not outcompeted by the wt virus throughout the course of the experiment. This finding was further substantiated by using a 10-fold excess of mutant over wt CVB3 (1:10 ratio, wt to mutant), which

Received 28 October 2013 Accepted 19 December 2013


Published ahead of print 26 December 2013

Editor: D. S. Lyles

Address correspondence to Frank J. M. van Kuppeveld, f.j.m.vankuppeveld@uu.nl.

Copyright © 2014, American Society for Microbiology. All Rights Reserved.

doi:10.1128/JVI.03177-13



A comparable fitness of two virus variants *in vitro* does not necessarily imply a comparable virulence in the infected host. Importantly, these growth competition experiments were performed in the absence of a PI4KIII β inhibitor. Since we previously demonstrated that the presence of such inhibitor induced a 1- to 2-h delay in a single replication cycle of the mutant virus *in vitro*, we wondered whether this delay *in vitro* might be translated to an impaired virulence *in vivo* (8). To this end, we studied the replication of both viruses in a CVB-induced pancreatitis mouse model that has been described previously (9). In this model, virus-induced pancreatic tissue damage is the most prominent symp-

tom and, hence, it served as the basis to study viral fitness. Employing this model, we compared the virulence and pathogenicity of wt CVB3 and CVB3 3A-H₅₇Y, either in the absence or presence of compound 2 (a recently published PI4KIIIβ inhibitor of enterovirus replication both *in vitro* and *in vivo* [7]). Mice (*n* = 5 per group) were infected intraperitoneally with equivalent amounts (5×10^5 TCID₅₀/ml) of either wt virus or CVB3 3A-H₅₇Y, which was previously determined to result in a peak of pancreatic symptoms at day 3 postinfection (data not shown). Immediately after infection, mice were treated (via the subcutaneous route) twice daily with 50 mg/kg of body weight/day of compound 2 or were left untreated (Fig. 2). At 3 days postinfection, the mice were sacrificed, and following extensive transcardial perfusion with phosphate-buffered saline, the pancreas was removed. One part of the pancreas was fixed in 4% formaldehyde and embedded in paraf-




FIG 2 Effects of compound 2 in CVB3-induced pancreatitis. Mice were infected with wt or 3A-H₅₇Y CVB3 and treated subcutaneously twice a day with 50 mg/kg/day of compound 2 or were left untreated. Effects on histopathology scores (A), virus replication (B), and biochemical parameters for pancreatitis (C) are shown. Data are presented as means \pm standard deviations ($n = 5$). Statistical significance was calculated by means of the Mann-Whitney U test.

fin. Tissue sections were stained with hematoxylin and eosin, and histopathological damage was quantified using a standardized scoring system ranging from 0 (absence of damage) to 3 (diffuse damage throughout the tissue) (10). Histopathological analysis revealed similar scores for interstitial inflammation, necrosis, and edema in mice infected with either wt virus or 3A-H₅₇Y CVB3. Compound 2 provided complete protection against all parameters of pancreatitis in mice infected with wt CVB3, whereas no protective effects were observed in mice infected with CVB3 3A-H₅₇Y (Fig. 2A). Interestingly, the signs of inflammation in these mice were comparable to those of untreated infected mice, suggesting a similar virulence even in the presence of the compound.

Another part of the pancreas was homogenized in saline using mechanical disruption (Precellys 24; Bertin) to quantify infectious virus titers by means of endpoint titrations, expressed as the 50% cell culture infectious dose (TCID₅₀) per ml (Fig. 2B). As a marker for pancreatitis, we also quantified the serum amylase and lipase levels, using an enzymatic colorimetric reaction (Cobas/Roche) on the modular P analyzer (Roche Diagnostics). To this end, 500 μ l of blood was collected by cardiac puncture before the transcardial perfusion, and following 1 h of incubation at room temperature, blood was centrifuged at 13,000 rpm for 10 min (Fig. 2C). Similar to the histopathological analysis, the virus titers and amylase/lipase levels of untreated infected animals did not differ

significantly from those of the treated, CVB3 3A-H₅₇Y-infected animals. On the contrary, mice treated with compound 2 and infected with wt CVB3 exhibited a marked reduction of virus titers ($\sim 4 \log_{10}$) and normalization of amylase and lipase levels.

Overall, our data demonstrate that, upon acquiring an H₅₇Y mutation in protein 3A, CVB3 exhibited a reduced drug susceptibility to PI4KIII β inhibitors not only *in vitro* but also in the infected host. Although our previous *in vitro* studies suggested a reduced fitness of this mutant CVB3 in the presence of a PI4KIII β inhibitor, this was not translated to an impaired virulence or pathogenicity *in vivo* (either in the absence or presence of such an inhibitor). Furthermore, we show that in a 1:1 mixture with wt virus, CVB3 3A-H₅₇Y was not outcompeted by wt virus but remained present in the viral population throughout the course of the experiment. Collectively, these data suggest that upon the emergence of CVB3 3A-H₅₇Y *in vivo* under the selective pressure of a PI4KIII β inhibitor, this mutant virus has sufficient fitness to compete with wt virus and to establish a resistant virus population with a similar virulence. However, given the lengthy selection process *in vitro* and the fact that, thus far, only one 3A-H₅₇Y isolate has been recovered from a patient (GenBank accession number [JQ040513](https://www.ncbi.nlm.nih.gov/nuclseq/JQ040513)), it remains questionable whether this mutation would emerge during a short-acting treatment of these acute infections in infected patients.

ACKNOWLEDGMENTS

We acknowledge Carolien De Keyzer and Kim Donckers for their excellent assistance in performing the animal experiments and generating the *in vivo* data.

The research leading to these results has received funding from the European Union Seventh Framework Program (FP7/2007-2013) under SILVER grant agreement number 260644, the KU Leuven Geconcerteerde Onderzoeksactie (GOA/10/014), the Netherlands Organization for Scientific Research (NWO-VENI-863.12.005 to H.M.V.D.S. and NWO-VICI-91812628 to F.J.M.V.K.) and the European Union 7th Framework Program (EUVIRNA Marie Curie Initial Training Network), grant agreement number 264286.

REFERENCES

1. Arita M, Kojima H, Nagano T, Okabe T, Wakita T, Shimizu H. 2011. Phosphatidylinositol 4-kinase III beta is a target of enviroxime-like compounds for antipoliomyelitis activity. *J. Virol.* 85:2364–2372. <http://dx.doi.org/10.1128/JVI.02249-10>.
2. Arita M, Takebe Y, Wakita T, Shimizu H. 2010. A bifunctional anti-enterovirus compound that inhibits replication and the early stage of enterovirus 71 infection. *J. Gen. Virol.* 91:2734–2744. <http://dx.doi.org/10.1099/vir.0.023374-0>.
3. Arita M, Wakita T, Shimizu H. 2009. Cellular kinase inhibitors that suppress enterovirus replication have a conserved target in viral protein 3A similar to that of enviroxime. *J. Gen. Virol.* 90:1869–1879. <http://dx.doi.org/10.1099/vir.0.012096-0>.
4. De Palma AM, Thibaut HJ, van der Linden L, Lanke K, Heggermont W, Ireland S, Andrews R, Arimilli M, Al-Tel TH, De Clercq E, van Kuppeveld FJ, Neyts J. 2009. Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307. *Antimicrob. Agents Chemother.* 53:1850–1857. <http://dx.doi.org/10.1128/AAC.00934-08>.
5. Heinz BA, Vance LM. 1995. The antiviral compound enviroxime targets the 3A coding region of rhinovirus and poliovirus. *J. Virol.* 69:4189–4197.
6. Heinz BA, Vance LM. 1996. Sequence determinants of 3A-mediated resistance to enviroxime in rhinoviruses and enteroviruses. *J. Virol.* 70:4854–4857.
7. van der Schaar HM, Leyssen P, Thibaut HJ, de Palma A, van der Linden L, Lanke KH, Lacroix C, Verbeken E, Conrath K, Macleod AM, Mitchell DR, Palmer NJ, van de Poel H, Andrews M, Neyts J, van Kuppeveld FJ. 2013. A novel, broad-spectrum inhibitor of enterovirus replication that targets host cell factor phosphatidylinositol 4-kinase III β . *Antimicrob. Agents Chemother.* 57:4971–4981. <http://dx.doi.org/10.1128/AAC.01175-13>.
8. van der Schaar HM, van der Linden L, Lanke KH, Strating JR, Purstinger G, de Vries E, de Haan CA, Neyts J, van Kuppeveld FJ. 2012. Coxsackievirus mutants that can bypass host factor PI4KIII β and the need for high levels of PI4P lipids for replication. *Cell Res.* 22:1576–1592. <http://dx.doi.org/10.1038/cr.2012.129>.
9. De Palma AM, Verbeken E, Van Aelst I, Van den Steen PE, Opdenakker G, Neyts J. 2008. Increased gelatinase B/matrix metalloproteinase 9 (MMP-9) activity in a murine model of acute coxsackievirus B4-induced pancreatitis. *Virology* 382:20–27. <http://dx.doi.org/10.1016/j.virol.2008.08.046>.
10. De Palma AM, Thibaut HJ, Li S, Van AI, Dillen C, Swinnen M, Verbeken E, Neyts J, Opdenakker G. 2009. Inflammatory rather than infectious insults play a role in exocrine tissue damage in a mouse model for coxsackievirus B4-induced pancreatitis. *J. Pathol.* 217:633–641. <http://dx.doi.org/10.1002/path.2501>.